Cargando…
The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2)
BACKGROUND: Imatinib represents the first in a class of drugs targeted against chronic myelogenous leukemia to enter the clinic, showing excellent efficacy and specificity for Abl, Kit, and PDGFR kinases. Recent screens carried out to find off-target proteins that bind to imatinib identified the oxi...
| Autores principales: | , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2009
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2655291/ https://www.ncbi.nlm.nih.gov/pubmed/19236722 http://dx.doi.org/10.1186/1472-6807-9-7 |